Previous 10 | Next 10 |
2024-03-18 17:35:56 ET More on Precigen Precigen: RRP Targeting With AdenoVerse Technology Platform Precigen gets EU orphan drug status for respiratory tract drug Seeking Alpha’s Quant Rating on Precigen Historical earnings data for Precigen Fi...
2024-03-18 17:35:27 ET More on etc. A Bitcoin Strategy Using The 200-Day Simple Moving Average (Technical Analysis) Madrigal: Accelerated Rezdiffra Approval Puts It In The NASH Lead Re-Emerging Markets Biggest stock movers today: NVDA, GOOG, FOUR and more ...
2024-03-17 08:20:00 ET Wall Street has reached a notable lull in the pace of quarterly releases. Still, investors are eagerly anticipating important announcements from FedEx ( NYSE: FDX ) and a set of prominent consumer brands, such as Nike ( NYSE: NKE ), Lululemon Athl...
Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis PR Newswire GERMANTOWN, Md. , March 12, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq:...
Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th PR Newswire GERMANTOWN, Md. , March 5, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene an...
Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...
Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference PR Newswire GERMANTOWN, Md. , Feb. 6, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene...
2024-01-19 19:39:39 ET Summary FDA agreed to allow phase 1/2 study to serve as the basis for being able to file for Accelerated Approval of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis. A BLA filing of PRGN-2012 for the treatment of patients wi...
2024-01-16 09:33:30 ET More on Precigen Precigen: Big Ambitions But Outstanding Funding Concerns Seeking Alpha’s Quant Rating on Precigen Historical earnings data for Precigen Financial information for Precigen For further details see: Prec...
Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission PR Newswire – Designation is an important step toward bringing this potentially life-changing therapy to European patients ...
News, Short Squeeze, Breakout and More Instantly...
Precigen Inc. Company Name:
PGEN Stock Symbol:
NASDAQ Market:
Precigen Reports First Quarter 2024 Financial Results and Business Updates PR Newswire – Pivotal Phase 2 study data of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis to be presented at the 2024 ASCO Annual Meeting as a late-breaking or...
Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting PR Newswire GERMANTOWN, Md. , May 8, 2024 /PRNewswire/ -- Pr...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...